RecruitingNot ApplicableNCT02808572

New Biomarkers of Bone Mineral Metabolism as Cardiovascular Risk Factors in Chronic Kidney Disease Patients

New Biomarkers of Bone and Mineral Metabolism as Risk Factors for Morbidity/Mortality in Chronic Kidney Disease Patients Not Requiring Dialysis

Sponsor

University Hospital, Montpellier

Enrollment

250 participants

Start Date

Mar 12, 2013

Study Type

INTERVENTIONAL

Conditions

Chronic Kidney Disease

Summary

To evaluate the relationships between bone mineral metabolism markers (osteoprotegerin, fibroblast growth factor 23) at inclusion and the occurence of cardiovascular events during a 7 year follow-up.

Eligibility

Min Age: 18 YearsMax Age: 95 Years

Plain Language Summary

Simplified for easier understanding

This study is investigating whether certain new markers in the blood related to bone and mineral health can predict heart disease risk in people with chronic kidney disease — long-term reduced kidney function. **You may be eligible if...** - You have been diagnosed with chronic kidney disease - You are not currently on dialysis (a machine-based kidney cleaning treatment) - You have signed a consent form agreeing to participate **You may NOT be eligible if...** - You are pregnant - Your kidney disease is so advanced that you require dialysis Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALPlasma osteoprotegerin level

dosage of plasma osteoprotegerin

BIOLOGICALPlasma fibroblast growth factor 23 level

dosage of plasma fibroblast growth factor 23

PROCEDUREVascular calcification score

measurement of vascular calcification score by multidetection computerized tomography

Locations(7)

AIDER

Montpellier, France

CHU Montpellier, Cardiology department

Montpellier, France

CHU Montpellier, Endocrinology department

Montpellier, France

CHU Montpellier, Intensive care unit

Montpellier, France

CHU Montpellier, Internal medicine department

Montpellier, France

CHU Montpellier, Nephrology department

Montpellier, France

AIDER

Saint-Jean-de-Védas, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT02808572

Related Trials

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of OJR520 in Healthy Volunteers and Participants With Chronic Kidney Disease

NCT072350592 locations

A Natural History Study of Metabolic Sizing in Health and Disease

NCT053987831 location

A Study to Investigate IGT-303 in Healthy Volunteers and Participants With Chronic Kidney Disease

NCT072316795 locations

A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids)

NCT07107945102 locations

OPTIMISE-CKD Study_Dapagliflozin Effectiveness in CKD

NCT074508201 location